The global migraine drugs market grew at a CAGR of around 14% during 2014-2019.
Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient’s medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.
A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. Besides this, the testing of migraine drugs for the treatment of the coronavirus disease (COVID-19) is expected to create a positive influence on the market growth. For instance, Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, which was examining Zavegepant for the treatment of acute migraines, has commenced the clinical trial on the same drug to mitigate the neuro-immune consequences among COVID-19 patients. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth. Looking forward, the analyst expects the global migraine drugs market to exhibit strong growth during the forecast period (2020-2025).
Key Market Segmentation: the analyst provides an analysis of the key trends in each sub-segment of the global migraine drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, treatment type, drug type, route of administration and distribution channel.
Breakup by Treatment Type: Abortive Treatment Preventive Treatment
Breakup by Drug Type: Triptans Ergot Alkaloids NSAIDs Acetylcholine Inhibitors/ Neurotoxins Ditans CGRP mAbs Others
Breakup by Route of Administration: Oral Injectable Others
Breakup by Distribution Channel: Hospital-Based Pharmacies Retail Pharmacies Others
Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa
Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.
Key Questions Answered in This Report: How has the global migraine drugs market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global migraine drugs market? What are the key regional markets? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the drug type? What is the breakup of the market based on the route of administration? What is the breakup of the market based on the distribution channel? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global migraine drugs market and who are the key players? What is the degree of competition in the industry?
Our reports have been used by over 10K customers, including:
106 pages •
By Euromonitor International
• Nov 2020
Consumer health value sales will continue to grow in 2020, despite the negative economic impact of COVID-19 on the economy. Lower purchasing power among middle-income consumers and the rising cost of healthcare in Argentina have fuelled a shift towards self-medication in recent years, thus encouraging preventive healthcare. Following this...
Migraine Drugs Market Research Report by Therapeutic Class (Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, and Pain Reliever), by Treatment Type (Abortive and Preventive), by Route of Administration, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The...
Rosacea - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape. Rosacea is a chronic and potentially life-disruptive disorder primarily of the...
Dysmenorrhea Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Dysmenorrhea Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dysmenorrhea Clinical trials scenario.This report provides top line data relating to the clinical trials on Dysmenorrhea. Report...
Digital Migraine Treatment Devices Market Research Report by Product Type (Occipital Nerve Stimulation Digital Migraine Treatment Devices, Single-pulse Transcranial Magnetic Stimulation Digital Migraine Treatment Devices, Supraorbital Stimulation Digital Migraine Treatment Devices, and Vagus Nerve Stimulation Digital Migraine Treatment...
Calcitonin Gene Related Peptide - Pipeline Review, H2 2020 Summary According to the recently published report ’Calcitonin Gene Related Peptide - Pipeline Review, H2 2020’; Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules...
122 pages •
By Euromonitor International
• Oct 2020
The outbreak of Coronavirus (COVID-19) and the subsequent lockdown have had a strong effect on consumer health in Belgium. Thus, there have been significant switches from category to category, as well as one distribution channel to another due to strong restrictions on retailing. Consumer Health in Belgium report offers a comprehensive...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.